

Antimicrobial activity of *Salvadora persica* on *Streptococcus pneumoniae*.

Mohammed K. Almaghrabi*

Department of Microbiology and Clinical Parasitology, College of Medicine, King Khalid University, Abha, Saudi Arabia

Abstract

Streptococcus pneumoniae is an important pathogen, which is mainly the causative agent of pneumonia. The limited treatment and control options mean refers an urgent need for novel effective therapies to treat infected patients. The study has described one approach of controlling and treating this pathogen using *Salvadora persica*. An extract from different parts of this plant has been used including twigs, fruit, and root. All extracts were shown to clear pneumococci lawns on solid media. However, fruit extract showed a considered reduction in pneumococcal colony forming unit (CFU) in liquid culture. This represents a promising therapeutic strategy against pneumococcal infection in particular by highly invasive strains that have evaded vaccination, or are resistant to existing antibiotics.

Keywords: Antimicrobial, *Salvadora persica*, *Streptococcus pneumoniae*, Fruit extract, Resistance, Antibiotics.

Accepted on October 22, 2018

Introduction

Streptococcus pneumoniae is a major cause of pneumonia, sepsis, and meningitis, responsible for over 1.2 million deaths per year. Worldwide, pneumonia is the leading infectious cause of mortality among children and adults, with *Streptococcus pneumoniae* being the most commonly recovered isolate [1]. In developing countries, respiratory tract infections frequently progress to fatal sepsis and meningitis, particularly in the immunocompromised, young, and elderly [2]. Approximately 50% of deaths occur during the first 48 h of treatment, where antibiotic therapy affects mortality during this period [3-5]. Furthermore, rates of antibiotic resistance are rising with over one third of isolates in the US and parts of Europe showing reduced susceptibility to penicillin [6,7]. As, pneumococcal conjugate vaccines have resulted in a decline in invasive disease caused by pneumococcal serotypes included in the vaccine [8], non-vaccine serotypes have been shown to cause replacement disease. Another antimicrobial agent should be discovered to be used against this bacterium to address these important clinical challenges and provide cross serotype protection against pneumococcal infection. One such source of a new antimicrobial; is a *Salvadora persica*.

S. persica, locally called miswak is an ancient toothbrush belongs to the Salvadoraceae family. It is scientifically proven to prevent dental decay when it is used for tooth cleaning [9]. Different parts of this plant such as root, twigs, and stem are used in Middle East to obtain dental hygiene. The use of high concentration of *S. persica* extract gave similar activity to that obtained by using oral disinfectants and anti-plaque agents, such as triclosan and chlorhexidine gluconate [10,11]. Studies have shown that miswak extract contains antibacterial,

antifungal and anti-plasmodial effects [12-14]. The present study has investigated the impact of *S. persica* root, fruit, and twig extract on the most common causative community-acquired pneumonia, *Streptococcus pneumoniae*.

Materials and Methods

Plant materials

Fresh and healthy root, fruit, and twigs of the plant *S. persica* were collected from local farms in Hali centre, Alqunfudah city, province of Makkah, Saudi Arabia (Figure 1). The collection of the plant component was undertaken in June 2014.



Figure 1. *Salvadora persica* tree; A: Twigs with fruits, B: Fruit and C: root.

Preparation of plant materials

Roots, twigs, and fruit of *S. persica* were washed several times with water and then were left to dry in air. A 500 g of root and twigs were grinded and homogenized with 250 µl of water. Fruits were directly homogenized without the addition of

water. All different aqueous extracts were centrifuged and then filtered with 022 µm pore size filters.

Bacterial strain

Laboratory strain (D39) of *Streptococcus pneumoniae* was used in this study. The bacteria strain was provided from laboratory beads collection stocks of Professor Aras Kadioglu, University of Liverpool, United Kingdom.

Culture media

Blood agar (Oxoid, UK) was prepared according to the manufacturer's instruction, autoclaved, cooled down, and 5% of horse blood was added. Medium then was dispensed at 20 ml per plate in 12 × 12 cm Petri dishes. Set plates were incubated overnight to ensure sterility before use.

Antimicrobial activity

Determination of zone of inhibition method: Antimicrobial activity was undertaken using spot test as described by Armon and Kott [15]. 500 µl of exponential growth of strain D39 was added to 3 ml of 0.4% sloppy agar (3.7 g brain heart infusion (BHI) broth base and 0.4 g of agar). The mixture was then poured on BHI agar base, distributed all over the plate, and left on the bench to set. 10 to 20 µl of extract was spotted on the top of pneumococcal lawns, once lawns were made and the agar set. Spotted plates were left on the bench to dry and then incubated overnight at 37°C using an-aerobic conditions. The plates were observed the next day to monitor the presence of zone of killing, which indicate the antimicrobial activity.



Figure 2. Antimicrobial activity of *Salvadora persica* extracts on pneumococcal lawn (Right plate is a control and left plate tested culture which shown a clear zone of inhibition).

Antimicrobial effect on bacterial growth: Colony-forming units were enumerated using the Miles-Misra assay with some modifications to evaluate the effect of *S. persica* extract on pneumococcal growth. Triplicate dilutions of 10^{-1} of each plant extracts were made using BHI-serum broth (20% of foetal calf serum) and were kept for further processes. Tube of 10 ml of brain heart infusion (BHI) broth was inoculated with strain D39 and incubated overnight at 37°C. The following day, they were centrifuged at 1750 Xg for 15 min. The pellets were re-suspended in 1 ml of extract/BHI-serum broth, which were prepared earlier. 700 µl from the re-suspended pellets for each serotype was added to 10 ml of BHI-serum broth, which was

then incubated at 37°C. The blood agar plate was divided into six sections. Three drops of 20 µl of each culture were spotted over each section. The previous process was assessed on two plates and repeated twice. All plates were incubated in CO₂ gas jar at 37°C overnight. The following day, the dilution containing the optimum numbers of colonies (~200 colonies) was counted and calculated the viable count using the following formula;

$$\text{CFU per ml} = \text{Mean number of colonies in sector} \times \text{Dilution} \times 1000/60.$$

Results and Discussion

Determination of zone of inhibition method

A zone of killing on spotted areas has been observed (Figure 2). The zone of bacterial growth inhibition was very clear using all extract indicating that *S. persica* extracts have a bactericidal effect on *S. pneumoniae* growth.

Antimicrobial effect of *S. persica* extracts on pneumococcal growth in liquid culture

The effect of *S. persica* extracts on pneumococcal growth in liquid culture indicated that only fruit extract has shown the ability to suppress pneumococcal growth. The initial CFU counts of treated cultures were 10^7 and it continued at the same value using fruit extract for five hours. At the end of the experiment, fruit extract-treated culture CFU was approximately 1.25 log CFU lower than control. Whereas, viable count of those cultures which treated with root and twigs extract was only 0.1 log CFU lower than control (Figure 3). Fruit treated cultures have shown approximately 1.25 log CFU difference as compared to control; whereas, root and twigs treated cultures had no significant efficacy on pneumococcal CFUs.

The effect of *S. persica* extract on *S. pneumoniae* growth




Figure 3. Effect of *S. persica* extracts on pneumococcal growth in liquid culture.

Medicinal plant extracts are being increasingly reported as antimicrobial agents from different parts of the world. The World Health Organization (WHO) has estimated that the extraction or the active constituents of such plant are used as traditional medicine in 80% of the world's population [16]. Ancient Arabs were familiar to Miswak to clean their teeth and

get them white and shiny [15]. The same method of teeth cleaning approach was used in Japan and USA with different type of plants [17]. The efficacy of Miswak on different bacterial growth was extensively studied; including, *Staphylococcus aureus* [12], *Streptococcus fecalis* and *S.mutans* [18], *Candida albicans* [19], and *Candida* species [13].

In the present study, the extracts obtained from fruits, twigs, and root of *Salvadora persica* showed strong activity against *S. pneumoniae* wild type strains. The current results of this study might justify the ancient use of root and twigs of this plant as tooth brush. Zone of growth inhibition on pneumococcal lawn was observed by using extracts from twigs, fruits, and roots of *S. persica* that indicated their ability to kill pneumococcal cells. The effect of these extract on pneumococcal growth in liquid culture showed only fruit extract reduced pneumococcal CFUs in about one log difference as compared to controls. However, very small difference in log CFUs difference was obtained by using twigs and root extracts. The difference between the effect of twigs and root extract to clear pneumococci in lawn and broth might refer to the concentration of active material. Diluting the extracts during measuring their effect on pneumococcal in broth cultures might decrease the effect of antimicrobial agents indicating that the concentration of antimicrobial agent in fruit extract was higher than those in twigs and root extract.

Acknowledgement

The author is very thankful to all the associated personnel in any reference that contributed in/for the purpose of this research. Further, this research holds no conflict of interest and is not funded through any source.

References

1. Black RE, Cousens S, Johnson HL, Lawn JE, Rudan I, Bassani DG, Eisele T. Global, regional, and national causes of child mortality in 2008: a systematic analysis. *Lancet* 2010; 375: 1969-1987.
2. Gordon SB, Chaponda M, Walsh AL, Whitty CJ, Gordon MA, Machili CE, Molyneux ME. Pneumococcal disease in HIV-infected Malawian adults: acute mortality and long-term survival. *AIDS (London, England)* 2002; 16: 1409.
3. Imran MN, Leng PH, Yang S, Kurup A, Eng P. Early predictors of mortality in pneumococcal bacteraemia. *Ann Acad Med Singapore* 2005; 34: 426-431.
4. Mortensen EM, Restrepo MI, Anzueto A, Pugh JA. Antibiotic therapy and 48-hour mortality for patients with pneumonia. *Am J Med* 2006; 119: 859-864.
5. Tunkel AR. Adjunctive corticosteroids for adults in sub-Saharan Africa with bacterial meningitis. *Curr Infect Dis Rep* 2008; 10: 290-291.
6. Schito GC, Debbia EA, Marchese A. The evolving threat of antibiotic resistance in Europe: new data from the

- Alexander Project. *J Antimicrob Chemother* 2000; 46: 3-9.
7. Thornsberry C, Ogilvie P, Kahn J, Mauriz Y. Surveillance of antimicrobial resistance in *Streptococcus pneumoniae*, *Haemophilus influenzae*, and *Moraxella catarrhalis* in the United States in 1996-1997 respiratory season. *Diagn Microbiol Infect Dis* 1997; 29: 249-257.
8. Pilishvili T, Lexau C, Farley MM, Hadler J, Harrison LH, Bennett NM, Smith PJ. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. *J Infect Dis* 2010; 201: 32-41.
9. Salehi P, Sh MD. Comparison of the antibacterial effects of *persica* mouthwash with chlorhexidine on streptococcus mutans in orthodontic patients. *DARU J Pharm Sci* 2006; 14: 178-182.
10. Almas K. The effect of *Salvadora persica* extract (miswak) and chlorhexidine gluconate on human dentin: a SEM study. *J Contemp Dent Pract* 2002; 3: 27-35.
11. Almas K, Skaug N, Ahmad I. An in vitro antimicrobial comparison of miswak extract with commercially available non-alcohol mouthrinses. *Int J Dent Hyg* 2005; 3: 18-24.
12. Al lafi T, Ababneh H. The effect of the extract of the miswak (chewing sticks) used in Jordan and the Middle East on oral bacteria. *Int Dent J* 1995; 45: 218-222.
13. al-Bagieh NH, Idowu A, Salako NO. Effect of aqueous extract of miswak on the in vitro growth of *Candida albicans*. *Microbios* 1994; 80: 107-113.
14. Ali H, Konig GM, Khalid SA, Wright AD, Kaminsky R. Evaluation of selected Sudanese medicinal plants for their in vitro activity against hemoflagellates, selected bacteria, HIV-1-RT and tyrosine kinase inhibitory, and for cytotoxicity. *J Ethnopharmacol* 2002; 83: 219-228.
15. Bos G. The miswāk, an aspect of dental care in Islam. *Med Hist* 1993; 37: 68-79.
16. Bhalodia NR, Shukla VJ. Antibacterial and antifungal activities from leaf extracts of *Cassia fistula* L.: An ethnomedicinal plant. *J Adv Pharm Technol Res* 2011; 2: 104.
17. Hyson JM. History of the toothbrush. *J Hist Dent* 2003; 51: 73-80.
18. Almas K, Al-Bagieh NH. The antimicrobial effects of bark and pulp extracts of miswak, *Salvadora persica*. *BML* 1999; 60: 71-75.
19. Almas K, Stakiw JE. The effect of miswak extract from *Salvadora persica* stored for 18 years on microbes in vitro. *Egypt Dent J* 2000; 46: 227-230.

*Correspondence to

Mohammed K. Almaghrabi
Department of Microbiology and Clinical Parasitology
College of Medicine
King Khalid University
Saudi Arabia